Dominik Nörz1, Flaminia Olearo1, Stojan Perisic2, Matthias F Bauer3, Elena Riester4, Tanja Schneider5, Kathrin Schönfeld5, Tina Laengin5, Marc Lütgehetmann6. 1. Center for Diagnostics, Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf (UKE), Martinistraße 52, 20246, Hamburg, Germany. 2. Institute for Clinical Chemistry and Laboratory Medicine, Hospital of Stuttgart, Stuttgart, Germany. 3. Institute for Laboratory Medicine, Hospital of Ludwigshafen, Ludwigshafen, Germany. 4. Labor Augsburg MVZ GmbH, Augsburg, Germany. 5. Roche Diagnostics GmbH, Penzberg, Germany. 6. Center for Diagnostics, Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf (UKE), Martinistraße 52, 20246, Hamburg, Germany. mluetgeh@uke.de.
Abstract
INTRODUCTION: Molecular testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to suffer from delays and shortages. Antigen tests have recently emerged as a viable alternative to detect patients with high viral loads, associated with elevated risk of transmission. While rapid lateral flow tests greatly improved accessibility of SARS-CoV-2 detection in critical areas, their manual nature limits scalability and suitability for large-scale testing schemes. The Elecsys® SARS-CoV-2 Antigen assay allows antigen immunoassays to be carried out on fully automated high-throughput serology platforms. METHODS: A total of 3139 nasopharyngeal and oropharyngeal swabs were collected at 3 different testing sites in Germany. Swab samples were pre-characterized by reverse transcription real-time polymerase chain reaction (RT-qPCR) and consecutively subjected to the antigen immunoassay on either the cobas e 411 or cobas e 801 analyzer. RESULTS: Of the tested respiratory samples, 392 were PCR positive for SARS-CoV-2 RNA. Median concentration was 2.95 × 104 (interquartile range [IQR] 5.1 × 102-3.5 × 106) copies/ml. Overall sensitivity and specificity of the antigen immunoassay were 60.2% (95% confidence interval [CI] 55.2-65.1) and 99.9% (95% CI 99.6-100.0), respectively. A 93.7% (95% CI 89.7-96.5) sensitivity was achieved at a viral RNA concentration ≥ 104 copies/ml (~ cycle threshold [Ct] value < 29.9). CONCLUSION: The Elecsys SARS-CoV-2 Antigen assay reliably detected patient samples with viral loads ≥ 10,000 copies/ml. It thus represents a viable high-throughput alternative for screening of patients or in situations where PCR testing is not readily available.
INTRODUCTION: Molecular testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to suffer from delays and shortages. Antigen tests have recently emerged as a viable alternative to detect patients with high viral loads, associated with elevated risk of transmission. While rapid lateral flow tests greatly improved accessibility of SARS-CoV-2 detection in critical areas, their manual nature limits scalability and suitability for large-scale testing schemes. The Elecsys® SARS-CoV-2 Antigen assay allows antigen immunoassays to be carried out on fully automated high-throughput serology platforms. METHODS: A total of 3139 nasopharyngeal and oropharyngeal swabs were collected at 3 different testing sites in Germany. Swab samples were pre-characterized by reverse transcription real-time polymerase chain reaction (RT-qPCR) and consecutively subjected to the antigen immunoassay on either the cobas e 411 or cobas e 801 analyzer. RESULTS: Of the tested respiratory samples, 392 were PCR positive for SARS-CoV-2 RNA. Median concentration was 2.95 × 104 (interquartile range [IQR] 5.1 × 102-3.5 × 106) copies/ml. Overall sensitivity and specificity of the antigen immunoassay were 60.2% (95% confidence interval [CI] 55.2-65.1) and 99.9% (95% CI 99.6-100.0), respectively. A 93.7% (95% CI 89.7-96.5) sensitivity was achieved at a viral RNA concentration ≥ 104 copies/ml (~ cycle threshold [Ct] value < 29.9). CONCLUSION: The Elecsys SARS-CoV-2 Antigen assay reliably detected patient samples with viral loads ≥ 10,000 copies/ml. It thus represents a viable high-throughput alternative for screening of patients or in situations where PCR testing is not readily available.
Authors: Susannah L McKay; Farrell A Tobolowsky; Erin D Moritz; Kelly M Hatfield; Amelia Bhatnagar; Stephen P LaVoie; David A Jackson; K Danielle Lecy; Jonathan Bryant-Genevier; Davina Campbell; Brandi Freeman; Sarah E Gilbert; Jennifer M Folster; Magdalena Medrzycki; Patricia L Shewmaker; Bettina Bankamp; Kay W Radford; Raydel Anderson; Michael D Bowen; Jeanne Negley; Sujan C Reddy; John A Jernigan; Allison C Brown; L Clifford McDonald; Preeta K Kutty Journal: Ann Intern Med Date: 2021-04-27 Impact factor: 25.391
Authors: Zsὁfia Iglὁi; Jans Velzing; Janko van Beek; David van de Vijver; Georgina Aron; Roel Ensing; Kimberley Benschop; Wanda Han; Timo Boelsums; Marion Koopmans; Corine Geurtsvankessel; Richard Molenkamp Journal: Emerg Infect Dis Date: 2021-03-16 Impact factor: 6.883
Authors: Victor M Corman; Verena Claudia Haage; Tobias Bleicker; Marie Luisa Schmidt; Barbara Mühlemann; Marta Zuchowski; Wendy K Jo; Patricia Tscheak; Elisabeth Möncke-Buchner; Marcel A Müller; Andi Krumbholz; Jan Felix Drexler; Christian Drosten Journal: Lancet Microbe Date: 2021-04-07
Authors: Lisa J Krüger; Mary Gaeddert; Frank Tobian; Federica Lainati; Claudius Gottschalk; Julian A F Klein; Paul Schnitzler; Hans-Georg Kräusslich; Olga Nikolai; Andreas K Lindner; Frank P Mockenhaupt; Joachim Seybold; Victor M Corman; Christian Drosten; Nira R Pollock; Britta Knorr; Andreas Welker; Margaretha de Vos; Jilian A Sacks; Claudia M Denkinger Journal: PLoS One Date: 2021-05-27 Impact factor: 3.240
Authors: Maniya Arshadi; Fatemeh Fardsanei; Behnaz Deihim; Zahra Farshadzadeh; Farhad Nikkhahi; Farima Khalili; Giovanni Sotgiu; Amir Hashem Shahidi Bonjar; Rosella Centis; Giovanni Battista Migliori; Mohammad Javad Nasiri; Mehdi Mirsaeidi Journal: Front Med (Lausanne) Date: 2022-04-07
Authors: Lukas E Brümmer; Stephan Katzenschlager; Mary Gaeddert; Christian Erdmann; Stephani Schmitz; Marc Bota; Maurizio Grilli; Jan Larmann; Markus A Weigand; Nira R Pollock; Aurélien Macé; Sergio Carmona; Stefano Ongarello; Jilian A Sacks; Claudia M Denkinger Journal: PLoS Med Date: 2021-08-12 Impact factor: 11.069